Patents by Inventor James Strong
James Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10253964Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: GrantFiled: July 25, 2016Date of Patent: April 9, 2019Assignee: Integra LifeSciences CorporationInventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Publication number: 20160334092Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: ApplicationFiled: July 25, 2016Publication date: November 17, 2016Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Patent number: 9400101Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: GrantFiled: November 25, 2014Date of Patent: July 26, 2016Assignee: Integra LifeSciences CorporationInventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Publication number: 20150153035Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: ApplicationFiled: November 25, 2014Publication date: June 4, 2015Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Patent number: 8899774Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: GrantFiled: March 22, 2011Date of Patent: December 2, 2014Assignee: Integra Lifesciences CorporationInventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Patent number: 8709443Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: November 2, 2011Date of Patent: April 29, 2014Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20120141426Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: November 2, 2011Publication date: June 7, 2012Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20120120635Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.Type: ApplicationFiled: March 22, 2011Publication date: May 17, 2012Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
-
Patent number: 8071087Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: July 22, 2010Date of Patent: December 6, 2011Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 8066985Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: November 25, 2008Date of Patent: November 29, 2011Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20110014155Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: July 22, 2010Publication date: January 20, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20090117082Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: November 25, 2008Publication date: May 7, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20090110665Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: November 3, 2008Publication date: April 30, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20090098089Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: October 16, 2008Publication date: April 16, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7476382Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: April 30, 2004Date of Patent: January 13, 2009Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7374752Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: August 11, 2004Date of Patent: May 20, 2008Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20080026048Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: May 30, 2007Publication date: January 31, 2008Applicant: Oncolytics Biotech Inc.Inventors: Patrick Lee, James Strong, Matthew Coffey
-
Patent number: 7300650Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: April 1, 2003Date of Patent: November 27, 2007Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20060164781Abstract: An electrical apparatus of an electric distribution power system includes an electrical device having a high voltage electrical terminal that may be energized, an exterior insulating housing, and an insulator. The exterior insulating housing surrounds and insulates the electrical device, and includes an opening through which the high voltage electrical terminal protrudes such that at least a portion of the high voltage electrical terminal is external to the exterior insulating housing. The insulator covers the electrical terminal and is attached to the exterior insulating housing such that no current flow path is provided through an interface between the insulator and the exterior insulating housing.Type: ApplicationFiled: January 25, 2006Publication date: July 27, 2006Inventors: James Strong, David Miller, Jonathan Woodworth
-
Publication number: 20060129058Abstract: A system for receiving at least one electromyogram signal representing physiological activity in a quadruped. The system may comprise a first probe and a wireless receiver in wireless communication with the first probe. Also, an electromyogram device for determining a neuromuscular balance of a quadruped. The device may comprise a first probe and a second probe. The device may also comprise a processor in communication with the first probe and the second probe. The processor may be configured to compare a first electromyogram signal captured from the first probe and a second electromyogram signal captured from the second probe. Additional embodiments include an electrode for receiving an electromyogram signal representing physiological activity in a quadruped and a method for analyzing the physiology of a quadruped.Type: ApplicationFiled: December 13, 2004Publication date: June 15, 2006Inventors: James Strong, George Power, Errin Miller